Back to top
more

Avinger (AVGR)

(Delayed Data from NSDQ)

$2.95 USD

2.95
11,379

-0.10 (-3.28%)

Updated May 21, 2024 03:59 PM ET

After-Market: $2.97 +0.02 (0.68%) 6:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 248)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Inogen (INGN) Tops Earnings & Revenues in Q4; View Upbeat

Inogen Inc. (INGN) reported fourth-quarter 2016 earnings of 25 cents per share, which surpassed both the Zacks Consensus Estimate by 15 cents and the year-ago figure by 11 cents.

    Varian (VAR): Calypso Tumor Tracking System Now in Brazil

    Varian Medical Systems, Inc. (VAR), recently announced that Moinhos de Vento Hospital has become the first cancer treatment center in Brazil with Varian's flagship product Calypso, a tumor tracking system for cancer treatment.

      Integer (ITGR) Beats Earnings and Revenue Estimates in Q4

      Integer Holdings (ITGR) reported adjusted earnings of 87 cents per share in the fourth quarter of 2016, lower than the year-ago quarter figure of 92 cents.

        Allscripts Launches Clinical Pathways for Cancer Treatment

        Allscripts Healthcare Solutions, Inc. (MDRX) recently announced the launch of Clinical Pathways program for the treatment of cancer.

          Patterson Companies (PDCO) Earnings Beat Estimates in Q3

          Patterson Companies Inc. (PDCO) reported third-quarter fiscal 2017 adjusted earnings of 58 cents per share from continuing operations, which came higher than the Zacks Consensus Estimate of 57 cents.

            Fresenius Medical (FMS) Tops Earnings in Q4, View Upbeat

            Fresenius Medical Care AG & Co. KGAA (FMS) reported adjusted earnings of 63 cents per American Depositary Share (ADS) in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 61 cents.

              Inovalon (INOV) Q4 Earnings In Line, Revenue Beat Estimates

              Inovalon Holdings, Inc. (INOV) reported fourth-quarter 2016 adjusted earnings of 2 cents per share, which came in line with the Zacks Consensus Estimate.

                Teleflex (TFX) Gains FDA Approval for TrapLiner Catheter

                Teleflex Incorporated (TFX) recently announced 510(k) clearance for its TrapLiner Catheter from the US FDA for a full fledged commercial launch in the country.

                  Wright Medical (WMGI) Posts Narrower-than-Expected Q4 Loss

                  Wright Medical Group N.V. (WMGI) reported adjusted loss of 6 cents per share in the fourth quarter of 2016, narrower than loss of 8 cents reported in the year-ago quarter and the Zacks Consensus Estimate of a loss of 11 cents.

                    DaVita (DVA) Ties Up with Cigna Arm, Expands in Los Angeles

                    DaVita HealthCare Partners Inc. (DVA), a leading provider of dialysis services, announced that HealthCare Partners, a unit within its medical group, has entered into a strategic partnership with Cigna, a global health insurance service company.

                      DENTSPLY (XRAY) Beats on Earnings in Q4, Misses Revenues

                      DENTSPLY SIRONA Inc. (XRAY) reported adjusted earnings per share of 67 cents in the fourth quarter of 2016, surpassing the Zacks Consensus Estimate by 2 cents.

                        Allscripts (MDRX) Q4 Earnings Miss Estimates, View Upbeat

                        Allscripts Healthcare Solutions, Inc.(MDRX) reported fourth-quarter 2016 earnings of 10 cents per share, which missed the Zacks Consensus Estimate by 2 cents.

                          DaVita (DVA) Earnings Beat Estimates, Revenues Lag in Q4

                          DaVita Inc. (DVA) reported fourth-quarter 2016 adjusted operating earnings of 98 cents per share that surpassed the Zacks Consensus Estimate of 91 cents.

                            Masimo Gets CE Mark for RRp on MightySat Rx Pulse Oximeter

                            Masimo Corporation (MASI) recently announced the receipt of CE mark approval for respiration rate measurement (RRp) on MightySat Rx fingertip pulse oximeter.

                              CryoLife (CRY) Earnings Beat Estimates, Revenues Lag in Q4

                              CryoLife, Inc. (CRY) posted fourth-quarter 2016 adjusted earnings per share of 12 cents, beating the Zacks Consensus Estimate of 8 cents.

                                Express Scripts (ESRX) Earnings Top, Revenues Lag in Q4

                                Express Scripts Holding Company (ESRX) posted fourth-quarter 2016 adjusted earnings per share of $1.88, beating the Zacks Consensus Estimate by a penny

                                  Varian (VAR) Eclipse Software Named Category Leader by KLAS

                                  Varian Medical Systems (VAR) recently announced that its Eclipse treatment planning software has been named 2017 Category Leader for Oncology Treatment Planning by KLAS.

                                    Becton, Dickinson Launches BD Resolve Early Access Program

                                    Leading global medical technology company, Becton, Dickinson and Company (BDX), popularly known as BD, recently announced an early access program for the BD Resolve Single-Cell Gene Expression platform.

                                      Tirthankar Chakraborty headshot

                                      New Strong Buy Stocks for February 14th

                                      Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

                                        Cerner (CERN) Q4 Earnings Meet, Revenues Miss Estimates

                                        Cerner Corp(CERN) reported adjusted fourth-quarter 2016 earnings of 57 cents per share, in line with the Zacks Consensus Estimate.

                                          Tirthankar Chakraborty headshot

                                          New Strong Buy Stocks for February 9th

                                          Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

                                            Luminex (LMNX) Posts Loss in Q4, Revenues Miss Estimates

                                            Luminex Corporation (LMNX) reported loss of 8 cents per share in the fourth quarter of 2016, comparing unfavorably with the Zacks Consensus Estimate of adjusted earnings of 4 cents per share.

                                              SurModics (SRDX) Beats Earnings & Revenue Estimates in Q1

                                              Surmodics, Inc. (SRDX) reported earnings of 19 cents per share in the first-quarter of fiscal 2017 surpassing the Zacks Consensus Estimate of 9 cents.

                                                Pacific Biosciences (PACB) Q4 Loss Narrower than Estimated

                                                Pacific Biosciences of California Inc. (PACB), a pioneer in the field of single molecule long resequencing, reported loss of 21 cents per share in the fourth quarter of 2016, 2 cents narrower than the Zacks Consensus Estimate.

                                                  athenahealth (ATHN) Beats on Q4 Earnings, Misses Revenues

                                                  athenahealth (ATHN) reported adjusted earnings of 42 cents per share, which beat the Zacks Consensus Estimate of 27 cents.